1-Methyl-4-(2-methylbutan-2-yl)pyrazole

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 1-Methyl-4-(2-methylbutan-2-yl)pyrazole
• 英文别名: 1-methyl-4-(2-methylbutan-2-yl)pyrazole
• 化学式: C₉H₁₆N₂
• 分子量: 152.24
• InChiKey: GWRDMZMGKKEZIB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  17.8
• 氢给体数：
  0
• 氢受体数：
  1

文献信息

• Neprilysin inhibitors
  申请人：THERAVANCE BIOPHARMA R&D IP, LLC

  公开号：US10336773B2

  公开（公告）日：2019-07-02

  In one aspect, the invention relates to compounds having the formula: where R1-R6, a, b, and X are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and processes and intermediates for preparing such compounds.

  一方面，本发明涉及具有以下式子的化合物： 其中 R1-R6、a、b 和 X 如说明书中所定义，或其药学上可接受的盐。这些化合物具有肾酶抑制活性。在另一方面，本发明涉及包含此类化合物的药物组合物；使用此类化合物的方法；以及制备此类化合物的工艺和中间体。
• 4,6,7-TRISUBSTITUTED 1,2-DIHYDROPYRROL[3,4-C]PYRIDIN/PYRIMIDIN-3-ONE DERIVATIVE AND USE
  申请人：Shanghai Haiyan Pharmaceutical Technology Co., Ltd.

  公开号：EP3689871B1

  公开（公告）日：2021-09-29
• 6-MEMBERED AZA-HETEROCYCLIC CONTAINING DELTA-OPIOID RECEPTOR MODULATING COMPOUNDS, METHODS OF USING AND MAKING THE SAME
  申请人：Trevena, Inc.

  公开号：US20170210725A1

  公开（公告）日：2017-07-27

  The present embodiments are directed, in part, to compounds, or pharmaceutically acceptable salts thereof, or pharmaceutical compositions thereof for modulating the activity of delta opioid receptor, biased and/or unbiased, and/or methods for treating pain, migraines, headaches, depression, Parkinsons Disease, anxiety, and/or overactive bladder, and other disorders and conditions described herein or any combination thereof.
• THERAPEUTIC COMPOUNDS AND USES THEREOF
  申请人：GENENTECH, INC.

  公开号：US20180086720A1

  公开（公告）日：2018-03-29

  The present invention relates to compounds of formula (I): and salts thereof, wherein: R 1 -R 4 have any of the values defined in the specification, and compositions and uses thereof. The compounds are useful as inhibitors of BRG1, BRM and/or PB1. Also included are pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various BRG1-mediated disorders, BRM-mediated disorders and/or PB1-mediated disorders.
• NEPRILYSIN INHIBITORS
  申请人：THERAVANCE BIOPHARMA R&D IP, LLC

  公开号：US20180194776A1

  公开（公告）日：2018-07-12

  In one aspect, the invention relates to compounds having the formula: where R 1 -R 6 , a, b, and X are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and processes and intermediates for preparing such compounds.